Clinical Results of abaloparatide for osteoporosis treatment

Clinical Results of abaloparatide for osteoporosis treatment - Clinical Results of abaloparatide for osteoporosis treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057023

Enrollment

500

Registered

2025-03-01

Start date

2022-08-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe osteoporosis with a history of 1) fractures in two or more locations 2) YAM < 60% 3) a history of one fracture + YAM < 65% 4) vertebral fracture collapse rate > 40%. Patients who can provide written consent regarding this study.

Exclusion criteria

Exclusion criteria: Patients who are contraindicated or require caution when administering abaloparatide Malignant tumors Patients who are currently pregnant, breastfeeding, or wish to become pregnant Individuals who are unable to self-inject Individuals who cannot provide consent for research

Design outcomes

Primary

Measure	Time frame
Changes in lumbar and proximal femur bone mineral density, changes in bone metabolism markers, incidence of fractures, and incidence of side effects after 18 months of abaloparatide injections	—

Secondary

Measure	Time frame
Changes in lumbar spine and proximal femur bone mineral density, changes in bone metabolism markers, incidence of fractures, and incidence of side effects in sequential therapy after abaloparatide treatment.	—

Countries

Japan

Contacts

Public ContactRui Niimi

Niimi orthopaedics surgery clinic Orthopaedic surgery

furikakefuri@hotmail.co.jp0594332133

Outcome results